Abcam, ab247408, Anti-UBE2I / UBC9 antibody [EP2938Y] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal UBE2I / UBC9 antibody. Carrier free. Suitable for IP, WB, IHC-P, ICC/IF, Flow Cyt (Intra) and reacts with Human, Rat, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP2938Y,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:ICC/IF, Flow Cyt (Intra), IHC-P, WB, IPSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab247408 is the carrier-free version of
ab75854
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
UBE2I also known as UBC9 is a small ubiquitin-related modifier (SUMO) conjugating enzyme. It plays an important role in the SUMOylation process which modifies proteins by attaching sumo proteins to them altering their function. This protein has a molecular mass of approximately 18 kDa. UBE2I is expressed broadly across various tissues demonstrating its significance in cellular processes.
Biological function summary
The SUMO conjugating enzyme UBE2I is part of the SUMOylation complex which includes the SUMO E1 enzyme and SUMO E3 ligase. It facilitates the attachment of SUMO proteins to target proteins which can influence protein stability localization and interaction with other proteins. This modification usually regulates important cellular functions such as transcription DNA repair and cell cycle progression.
Pathways
Proteins modified by UBE2I participate in significant biological pathways such as the DNA damage response and cell cycle regulation. In the DNA damage response UBE2I works with proteins such as p53 and BRCA1 to maintain genomic stability. In cell cycle pathways interactions with proteins like cyclin D1 and CDK inhibitors help control cellular proliferation by SUMOylating key regulatory proteins.
UBE2I has been implicated in cancer and neurodegenerative diseases. Altered SUMOylation by UBE2I can lead to the dysfunction of tumor suppressor proteins like p53 contributing to cancer development. In neurodegenerative diseases abnormal SUMOylation might affect proteins like tau which can lead to the progression of conditions such as Alzheimer's disease. The role of UBE2I in these disorders highlights it as a potential therapeutic target in addressing these conditions.